Free Newsletter
Daiichi goes to bond market for refinancing
Free newsletter via e-mail
Tools
Daiichi Sankyo, Japan's third-largest drugmaker, plans to sell as much as $3.12 billion in bonds to refinance a loan taken for its $5 billion acquisition of Ranbaxy Laboratories. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: